Drug Trial Radar · NCT07831577
Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 2027
Primary completion
Oct 2029
Study completion Oct 2030
Sponsor
- Lead sponsor
- Genascence CorporationIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if GNSC-001 works to treat knee osteoarthritis in adults. It will also learn about the safety of GNSC-001. The main questions it aims to answer are: 1. Does GNSC-001 lower daily knee joint pain and improve function in participants? 2. What medical problems do participants have when taking GNSC-001? Researchers will compare GNSC-001 to a placebo (a look-alike substance that contains no drug) to see if GNSC-001 works to treat knee osteoarthritis. Participants will: 1. Receive a single injection of immune-modulation, and GNSC-001 or a placebo, in their knee 2. Take an oral immune-modulating pill every day for the first 22 days 3. Visit the clinic at least 9 times over 2 years for checkups and tests 4. Keep a diary of their symptoms and the number of times they use a rescue medication
Conditions
- Knee Arthritis Osteoarthritis
- Knee Arthritis, Osteoarthritis
- Knee Arthritis
- Knee Arthritis Disease
- Osteo Arthritis of the Knee
- Osteoarthritic Knee Pain
- Osteoarthritis (OA) of the Knee
- Osteo Arthritis Knee
- Pain (Knee)
Interventions
Gene Therapy GNSC-001Drug
Single intra-articular injection into target knee
PlaceboDrug
Single intra-articular injection into target knee
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in OA pain as assessed by the Weekly Average of Daily Pain (WADP) Numeric Rating Scale (NRS) at Week 52Time frame: Baseline and Week 52
- Change from baseline in the function subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at Week 52Time frame: Baseline and Week 52
- Incidence and severity of treatment emergent adverse events (TEAEs), events of clinical interest (ECIs), and serious adverse events (SAEs)Time frame: From enrollment to the end of study at 104 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.